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ABSTRACT
Objectives: This study evaluated the economic implications of results
obtained by the Stroke Prevention by Aggressive Reduction in Cholesterol
Levels (SPARCL) trial.
Methods: To enable long-term projection of the trial results, a discrete
event simulation of the course of clinical care after a recent stroke or
transient ischemic attack (TIA)was developed. It generates pairs of identical
patients; both receive usual care, one receives atorvastatin in addition. Their
clinical course is simulated based on their risk of stroke, cardiovascular
events, and case fatality rates taken from SPARCL, life expectancy from
Saskatchewan Health data, and utility weights from literature. Costs, from
a US health-care payer perspective in 2005 US dollars, were estimated for a
within-trial 5-year period; survival and quality-adjusted life-years (QALYs)
were extrapolated over a patient’s lifetime; all discounted at 3%/year.
Results: The prevention of stroke, coronary, and other cardiovascular
events expected with atorvastatin translates to mean gains of 0.155 life-
years gained and 0.172 QALYs per patient over their lifetime. Reducing
associated medical costs ($8405 vs. $11,237) but increasing drug costs
($13,984 vs. $8752) results in net $2400/patient, or $13,916/QALY
gained. Probabilistic sensitivity analysis indicates no simulations yield
ratios above $50,000/QALY.
Conclusion: Prescribing atorvastatin for patients with prior stroke or TIA
is expected to provide health beneﬁts at an acceptable cost in the United
States.
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Introduction
Patients who have had an ischemic cerebrovascular event (i.e.,
stroke or transient ischemic attack [TIA]) are at increased risk
for further strokes as well as coronary and other cardiovascular
events, despite a variety of preventive therapies [1]. Several
studies have suggested that HMG-CoA reductase inhibitors
(“statins”), a class of drugs that lowers the level of cholesterol in
the blood by reducing the production of cholesterol by the liver,
can reduce the risk of stroke in patients with coronary heart
disease and in those at increased risk for cardiovascular disease
[2–4]. The reduction in risk has been related to the extent to
which low density lipoprotein (LDL) cholesterol is lowered [5].
The Stroke Prevention by Aggressive Reduction in Choles-
terol Levels (SPARCL) trial established that atorvastatin 80 mg/
day reduces the risk of stroke, coronary, and other cardiovascular
events in patients who recently had a stroke or TIA but had no
known coronary disease [6]. During a median follow-up of 4.9
years, patients randomized to atorvastatin had a 16% lower risk
of subsequent stroke compared to usual care alone (P = 0.03, the
primary end point), and a 35% reduction in the risk of a major
coronary event (a secondary end point).
Despite these results, it is not clear whether adding atorvas-
tatin to poststroke care is economically attractive. Therefore, this
analysis was carried out to assess the economic implications
of adding atorvastatin 80 mg per day in secondary stroke
prevention.
Methods
SPARCL was a multinational clinical trial that randomly
assigned 4731 adults (at least 18 years of age) who had had a
stroke or TIA in the prior 6 months but no known coronary
disease to double-blind treatment with either atorvastatin 80 mg/
day or placebo [6]. Patients were enrolled between September
1998 and March 2001 and last study visit occurred in June 2005.
The primary outcome was the time from randomization to non-
fatal or fatal stroke. For more than 4.9 years of follow-up, less
than 5% of patients withdrew from the study and adherence to
active therapy was high. More patients receiving placebo dis-
continued treatment (20.2% vs. 15.4% of follow-up time for
primary end point, respectively), and began open-label, nonstudy
statin therapy (7.5% vs. 1.0% of follow-up time for the primary
end point, respectively). A 16% reduction in the risk of subse-
quent stroke and a 35% reduction in major coronary events with
atorvastatin were reported.
Model Overview
A discrete event simulation of the course after stroke or TIA was
developed. Discrete event simulation was selected as the model-
ing technique because it facilitates implementation of competing
time-dependent risks and consideration of the impact of patient
characteristics [7]. It permits patients to have the events in any
logical sequence or simultaneously. In addition, these events can
change the course of a given patient’s experience by inﬂuencing
that patient’s attributes and their likelihood of future events,
because there is no restriction on “memory.”
At the beginning of each simulation, individual patients were
generated and assigned speciﬁc characteristics (Fig. 1). Each
patient proﬁle included demographics (age, sex), an entry event
(stroke or TIA), relevant medical history (diabetes, hypertension,
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prior dyslipidemic medication), and a modiﬁed Rankin Scale
(mRS, a commonly used scale of disability or dependence in
activities of living, ranging from 0 = no symptoms to 5 = bedrid-
den). The assignment was done by Monte Carlo sampling from
the distributions of these characteristics in the SPARCL trial.
Although these distributions were sampled independently, some
of them were speciﬁed conditional on another, to address corre-
lation (e.g., baseline mRS was conditional on the type of entry
event, age distribution was conditional on the sex). Each patient
is also assigned a utility weight based on mRS at baseline.
After the patients were created, they were “twinned” to
produce two identical cohorts. This ensures that the comparisons
are not affected by differences in baseline characteristics and that
those events subject to chance (e.g., others death) but not to
treatment are treated equivalently across the groups. This also
substantially reduces nuisance variance and makes it possible to
obtain stable results with fewer model replications for each
analysis. Both patients in each pair received usual care (i.e.,
routine outpatient care, medications such as anticoagulants, beta
blockers, hormone replacement therapy, etc.), whereas only one
received atorvastatin 80 mg/day.
Each patient was modeled individually, with the path through
the simulation determined by his/her unique characteristics (such
as age, sex, medical history, prior TIA or stroke, etc.) as well as
by the events and treatments experienced during the simulation.
Each patient was exposed to various risks: stroke, myocardial
infarction (MI), TIA, unstable angina, revascularization, cardiac
death, and death due to other causes. The competing risks were
implemented by using a series of risk equations to translate the
patient’s risk factors (e.g., age, sex) into a distribution of failure
times speciﬁc to the individual. A time for each event can then be
assigned to each individual by sampling from the corresponding
distribution. For patients who received atorvastatin, the treat-
ment beneﬁts were taken into account by applying the hazard
ratio for each event type obtained from SPARCL before sampling
the times.
After the times for all events (clinical events, physician visit,
lab tests, change in location of care, and discontinuation of
atorvastatin) were assigned, the simulation compared them,
selected the next one, and scheduled the event at that time for
that patient. When the simulation arrived at that time, resource
use and costs were counted and survival and quality-adjusted
life-years (QALYs) up to that point were accrued. Any event time
that exceeded the model end time indicated that that particular
event would not occur during the selected time frame.
When a simulated stroke occurred, the patient was admitted
to the hospital and was assigned an updated mRS based on the
treatment-speciﬁc distributions of mRS associated with strokes in
SPARCL. An mRS of 6 indicated the patient had a fatal stroke.
Those with nonfatal stroke were assigned discharge location
of care and utility, which were determined based on their new
mRS. Upon occurrence of other clinical events (MI, TIA, un-
stable angina, and revascularization), a case fatality rate was
applied to determine if death occurred. If event was not fatal, the
subsequent management of the patient (i.e., location of care and
length of stay, other medications, routine outpatient care) was
determined. The corresponding costs of ongoing management
and patient’s utility were updated based on the event type and
future event risks were reestimated.
Simulated patients discontinued atorvastatin at the rate
observed in the SPARCL trial. If the patient discontinued atorv-
astatin, the beneﬁts were withdrawn immediately and times to
events were recalculated. Adverse events were not considered
in this model because the SPARCL trial revealed no signiﬁcant
differences in the incidence of serious adverse events [6]. Never-
theless, the cost of routine liver function monitoring as recom-
mended for patients on atorvastatin was modeled explicitly as
part of routine care. When the model period ended, all costs were
no longer accrued and atorvastatin effects were no longer
applied. The expected life-years (LYs) for each patient beyond the
end of model time were estimated based on the patient’s accrued
history through the model. QALYs were estimated from LYs
assuming that the ﬁnal utility weight remained constant for the
remaining life expectancy.
Cost-effectiveness ratios were calculated as the net cost of
atorvastatin divided by the net effectiveness. The latter was quan-
tiﬁed in terms of life-years gained (LYG) or QALYs gained.
Model Inputs
Model inputs were derived from SPARCL where available. Public
databases and literature were used to supplement these (Table 1).
The risk equations used to estimate baseline hazards for stroke,
MI, TIA, unstable angina, and revascularization (available online
as Supporting Information for this article) were derived from the
patient-level data collected in the SPARCL trial, using previously
published methods [8,9]. The functions developed included risk
factors such as age, sex, entry stroke and TIA. The case fatality
rates over the ﬁrst 28 days after a stroke (treatment dependent)
or MI were also estimated from SPARCL.
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Figure 1 Schematic presentation of the model
structure. MI, myocardial infarction; LFT, liver func-
tion test; LY, life-year; QALY, quality-adjusted life-
year;TIA, transient ischemic attack.
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Given insufﬁcient secondary events in SPARCL, a second
source was used to derive functions to predict cardiac death,
death due to other causes, and death from day 29 after admission
to hospital with an MI or stroke, and the risk of any subsequent
MIs or strokes (available online as Supporting Information for
this article). These functions were developed by analysis of spe-
ciﬁc subgroups of patients experiencing these events in a data
set obtained from the Saskatchewan Ministry of Health.
Saskatchewan Health maintains linkable databases that provide
information on all hospitalization, physician services, medica-
tions, and vital statistics for residents eligible for health coverage
in this Canadian province [10].
Because discontinuation was modeled as an explicit event in
the simulation (i.e., efﬁcacy was withdrawn when patients dis-
continued atorvastatin), to assure that data on treatment efﬁcacy
were not diluted by patients who had early discontinuation in
the SPARCL trial, the treatment efﬁcacy employed in this study
was based on per-protocol population analyses including only
patients who were exposed to treatment for at least 6 months.
Each patient’s utility at baseline and after subsequent stroke
was derived from the assigned mRS by applying published utility
weights [11]. Utility was updated multiplicatively with the cor-
responding utility weight when a clinical event occurred [12]. It
was assumed that TIA had no effect on utility. Note that a source
publication for utilities of MI and angina reports absolute dec-
rements rather than relative tariffs [13]. Application of absolute
decrements would overestimate the impact in case of multiple
comorbidities. Thus, the relative utilities were derived by using
the mean utility in the source population and the absolute
disutility of each event reported in the article.
Direct medical costs (Table 3) from the perspective of a US
payer were estimated in 2005 US dollars. Where 2005 values
were not available, older estimates were inﬂated using the
Medical Care Inﬂation Index for each of the relevant years [14].
Inpatient resource use and costs (accommodations, ancillary
services, and physician fees) were derived from all-payer 2003
discharge data from Arizona, California, Florida, Maryland,
Massachusetts, Texas, and Washington [15–21]. Relevant
patients were identiﬁed by the International Classiﬁcation of
Diseases (ICD-9) principal diagnosis code. The cost for revascu-
larization was a weighted average of coronary artery bypass
graft, percutaneous transluminal coronary angioplasty, and
carotid endarterectomy using the proportions observed in
SPARCL. Costs of subsequent care (rehabilitation, skilled
nursing facility, intermediate nursing facility, long-term care hos-
pital, residential care, or home with health-care services) were
developed from US database [15–24] and were applied to the
proportions of patients using them. These costs varied by type
Table 1 Model parameters, data sources, and values used in the base-case and sensitivity analyses
Parameter Source Base-case value Probabilistic sensitivity analysis
Demographics SPARCL See Table 2 Not varied
Risks of clinical events SPARCL and Saskatchewan
Health
From equations (see Supporting Information appendix) Multivariate normal covariance
matrix for each risk equation
Hazard ratios (atorvastatin vs.
usual care)
SPARCL (per-protocol analyses) Stroke: 0.82 Lognormal (0.82, 0.07)*†
MI: 0.58 Lognormal (0.58, 0.11)*†
TIA: 0.72 Lognormal (0.72, 0.08)*†
Angina: 0.55 Lognormal (0.55, 0.12)*†
Revascularization: 0.55 Lognormal (0.55, 0.08)*†
Stroke mRS distributions SPARCL mRS Usual care Atorvastatin Stroke case fatality (mRS6) was
varied using uniform (30%).
The mRS distribution for
stroke survivors (mRS0 to
mRS5) was adjusted
proportionately accordingly.
0 17% 18%
1 24% 22%
2 12% 14%
3 11% 12%
4 10% 8%
5 13% 17%
6 (fatal) 13% 9%
MI case fatality rate SPARCL 14% Uniform (30%)
Atorvastatin discontinuation rate SPARCL 5% per year Uniform (0%, 30%)
Costs [15–24] See Table 3 Lognormal distribution of the
mean and standard deviation
of each cost
Hospital discharge disposition SPARCL, [15–21] See Table 4 Not varied
Atorvastatin daily costs [28] $3.96 Not varied
Average daily drug costs for
usual care
[27,28] Stroke,TIA: $5.59‡ Not varied
MI,Angina: $7.76§
Revascularization: $7.04§
Stroke utility [11] mRS 0: 0.90 Beta (0.90, 0.03)¶
mRS 1: 0.79 Beta (0.79, 0.05)¶
mRS 2: 0.68 Beta (0.68, 0.14)¶
mRS 3: 0.65 Beta (0.65, 0.18)¶
mRS 4: 0.40 Beta (0.40, 0.11)¶
mRS 5: 0.32 Beta (0.32, 0.14)¶
Relative utility# [13] TIA: 1.00 Beta (0.95, 1.00)
Angina: 0.90 Beta (0.85, 0.95)
MI: 0.90 Beta (0.85, 0.95)
*Standard deviations were estimated from the 95% conﬁdence interval obtained from SPARCL.
†The parameters are natural logarithmic mean and natural logarithmic standard deviation of the values shown.
‡Includes antiplatelet agent and anticoagulant.
§Includes antihypertensive agents, acetylsalicylic acid, anticoagulant, anti-anginal agents, cardiac glycosides, beta blockers, diuretics, calcium channel blockers, and angiotensin-converting enzyme
inhibitors.
The values shown are mean and standard deviation of the beta distribution, not the parameters (i.e., alpha, beta).
¶Standard deviation was estimated from range obtained from the literature [11].
#Relative utilities for angina and MI were calculated from [13] using sample mean utility among the study population and the absolute disutility reported.TIA was assumed to have no effect
on utility.
MI, myocardial infarction; mRS, modiﬁed Rankin Scale; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels;TIA, transient ischemic attack.
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of event. Outpatient follow-up care (e.g., physician and other
professionals’ visits, monitoring lab tests) was also included
[25,26].
The 2005 Average Wholesale Price (AWP) of $3.96 per day
was used for atorvastatin 80 mg. For other medications that are
part of standard care, the recommended doses were identiﬁed
[27] and the AWP obtained from the 2005 RedBook [28] was
applied to calculate the average daily cost.
Analyses
The simulation was run for 10,000 patients over 5 years and 100
replications were done for each analysis to achieve stability in the
results. Costs and health beneﬁts were discounted at 3% per year.
Univariate sensitivity analyses were performed to examine the
effects of changes in several model parameters. Probabilistic sen-
sitivity analysis, where certain parameters were allowed to vary
between runs (1000 runs of 10,000 patients each), was carried
out to address the impact on outcomes resulting from varying
multiple parameters simultaneously (Table 1).
Validation
Face validity of the model was established by presenting the
inﬂuence diagram, model ﬂow charts, and ﬁnal model structure
to the SPARCL steering committee. Technical accuracy was
determined by performing extreme-value sensitivity analyses to
check for logical consistency. To test validity, input parameters
were set to be an exact match of the trial, and primary event rates
were compared. In this test, the model was run for 4 years (i.e.,
an average number of years per person in the trial, excluding lost
to follow-up) and predicted stroke rates of 5.64% with atorvas-
tatin and 6.66% with usual care, very close to those observed in
the SPARCL trial (5.60% and 6.57%, respectively).
Results
Compared to usual care, atorvastatin was estimated to prevent
225 strokes, 216 MIs, 335 TIAs, 77 unstable angina episodes,
and 377 revascularizations per 10,000 patients over 5 years. This
prevention of stroke, coronary, and other cardiovascular events
translated to 0.155 LYG and 0.172 QALYs gained per patient
over their lifetime (Table 5). Patients receiving atorvastatin had
lower medical costs ($8405 vs. $11,237) but higher drug costs
($13,984 vs. $8752), which resulted in a net increase of $2400/
patient compared with usual care (Table 6). Medications were
the largest cost component for both groups (44% for usual
care, 62% for atorvastatin), followed by acute care costs (42%
and 26%, respectively). Over 5 years, 908 hospitalizations were
Table 2 Baseline demographic and clinical characteristics of the
simulated cohort
Demographics Male (%) Female (%)
Sex 59.67 40.33
Age distribution (years)
21 to 30 0.28 0.42
31 to 40 2.87 2.11
41 to 50 12.29 11.73
51 to 60 27.42 24.37
61 to 70 33.09 27.72
71 to 80 21.92 28.47
81 to 90 2.13 5.03
91 to 95 0.00 0.15
Entry event parameters Stroke (%) TIA (%)
Entry event 69.10 30.90
Baseline modiﬁed Rankin scale
0 28.82 83.00
1 46.41 13.44
2 16.45 2.59
3 8.26 0.97
4 0.03 0.00
5 0.03 0.00
Medical history All (%)
Prior TIA 18.70
Prior stroke 14.90
Diabetes 16.20
Hypertension 60.40
Hypolipidemic medication 2.60
TIA, transient ischemic attack.
Table 3 Cost inputs for each location of care
Location of care Stroke ($) MI ($) TIA ($) Angina ($) Revascularization ($)*
Hospital (per stay) 16,003 35,079 9,104 8,932 40,077
Rehabilitation facility (per stay) 24,963 15,558 15,575 16,317 9,726
Long-term care hospital (per stay) 9,240 6,700 7,500 7,640 2,244
Residential care (per day) 118 116 109 110 N/A
*The cost for revascularization was a weighted average of coronary artery bypass graft, percutaneous transluminal coronary angioplasty, and carotid endarterectomy using the proportions
observed in Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL).
MI, myocardial infarction;TIA, transient ischemic attack.
Table 4 Hospital discharge disposition distributions
Location of care
Stroke*
MI (%) TIA (%) Angina (%) Revascularization (%)†mRS0 (%) 1 (%) 2 (%) 3 (%) 4 (%) 5 (%)
Rehabilitation facility 1 5 5 15 24 12 3 1 1 2
Long-term care hospital 0 0 3 0 6 19 14 9 2 5
Residential care 1 2 0 3 4 5 1 1 0 1
Home 98 93 92 82 66 64 82 89 97 92
*Discharge disposition conditioned on mRS at the time of stroke, derived from Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL).
†Distribution for revascularization was a weighted average of coronary artery bypass graft, percutaneous transluminal coronary angioplasty, and carotid endarterectomy using the proportions
observed in SPARCL.
MI, myocardial infarction; mRS, modiﬁed Rankin Scale;TIA, transient ischemic attack.
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avoided in the atorvastatin group, resulting in the largest cost
savings (decrease by 30% or $2547/patient), followed by post-
acute care (18% decrease, $274/patient). The incremental cost-
effectiveness ratio (ICER) of atorvastatin based on these analyses
was therefore $15,530/LYG or $13,916/QALY gained.
Sensitivity analyses indicated that the results are most sensi-
tive to the cost of atorvastatin and the patients’ age, and mod-
erately sensitive to the discount rate and sex (Fig. 2). The results
ranged from about $6500 to $21,000/QALY, with more favor-
able outcomes in patients with higher stroke risk, such as those
who were older, had a recent stroke (as opposed to TIA), or
males. Varying the price of atorvastatin by 25% changed the
ICER by $7381. Use of alternative sources of utility weights
[29,30], varying the discontinuation rate of atorvastatin, as well
as stroke and MI case fatality rates had little impact.
The probabilistic sensitivity analysis indicated that atorvasta-
tin was dominant in 5% of the simulations. The ICER was below
$15,000/QALY in 68% and in 95% it was below $30,890/
QALY. It was always below $50,000/QALY (Fig. 3).
Discussion
The SPARCL trial demonstrated that use of atorvastatin 80 mg
per day in patients with recent stroke or TIA but without coro-
nary disease prevents further strokes and other cardiovascular
events. The simulation presented here translated these health
beneﬁts into longer-term economic outcomes, survival, and
QALYs. Although use of atorvastatin over a 5-year period
increased drug costs, more than half of this increase was offset
by reductions in medical costs, largely due to reduction in acute
hospitalization and post–acute care costs. The resulting ICER
was in a range that suggests desirable economic value [31].
The economic efﬁciency estimated in this analysis compares
favorably to that of statin therapy for prevention of heart disease.
A study of several statin therapies for the prevention of cardio-
vascular disease resulted in ICERs between £1000/QALY and
£15,000/QALY (about US $2000 to 30,000) [32]. Another study
evaluating the cost-effectiveness of atorvastatin in prevention of
cardiovascular disease yielded ratios between £3000 and £6000
(US$6000 to 12,000) [33].
Notably, a large portion of hospitalizations avoided were
associated with MI and angina hospitalizations, as well as revas-
cularization procedures, compared with stroke and TIA hospi-
talizations. Although stroke is often one of the most common
secondary events after an ischemic stroke [34,35] and is asso-
ciated with high health-care costs [36], these patients are also
at high risk of coronary events, such as MI and cardiac death
[37,38]. In the SPARCL trial, there was a 35% reduction in
major coronary events and a 45% reduction in revascularization
procedures in the atorvastatin group versus placebo [6]. There-
fore, consideration of coronary as well as cerebrovascular risk in
this population is relevant to understanding the economic value
of statin therapies in this setting.
Based on results of SPARCL, a recent update to the American
Heart Association/American Stroke Association recommenda-
tions for prevention of stroke in patients with ischemic stroke or
TIA supports administration of intensive statin therapy even in
the absence of overt coronary disease [39]. This adds to their
prior recommendation for a target LDL-C of <100 mg/dl in
patients with comorbid coronary disease and <70 mg/dl for
patients at very high cardiovascular risk. Our results provide
additional support regarding the cost-effectiveness of the new
recommendation.
Discrete event simulation conceptualizes the course of disease
and its management in terms of the events and allows the model
to capture a complex pattern of events. This technique supported
implementation of competing time-dependent risks, allowed the
simulated patients to have multiple conditions simultaneously,
and kept track of the history of what happened to each indi-
vidual. An important aspect of this project was to conduct a
detailed economic evaluation and this was achieved by the
explicit modeling of the acute in-hospital stay, subsequent man-
agement in the immediate post-acute care (e.g., rehabilitation,
skilled nursing facility, nursing home), and routine care (e.g.,
physician ofﬁce visit) [7].
The model combined risk equations derived from patient-level
data from the SPARCL trial with other data such as those from
Saskatchewan Health. Data from secondary data sources pro-
vided risk estimates that could not be reliably derived from the
trial due to insufﬁcient events. Although there are inevitably some
differences between the Saskatchewan real-world population and
the SPARCL trial participants, the large sample size and long
follow-up supported the development of functions that captured
the time dependency of these risks, and allowed adjustments for
risk factors such as age, sex, and history of diabetes, stroke, TIA,
hypercholesterolemia, and hypertension. These factors allow
for adjustment to match the trial population. Use of pattern of
care data allowed explicit modeling of initial acute in-hospital
management, subsequent management in the immediate post-
acute care (e.g., rehabilitation, skilled nursing facility), and further
routine care (e.g., physician ofﬁce visit, professional visit).
There are, however, some important limitations to these
analyses. Although the structure allows for fully time-dependent
analysis, three of the risks (MI, unstable angina, and revascular-
ization) were assumed to be constant over time based on what
Table 5 Point estimates of health beneﬁts and cumulative costs pre-
dicted over 5 years in the base case (mean of 100 replications) and
cost-effectiveness results (with ﬁfth and 95th percentiles from the proba-
bilistic sensitivity analysis)
Outcome (mean per patient) Usual care Atorvastatin Net
Cumulative cost
Discounted* $19,989 $22,389 $2,400
Undiscounted $21,424 $24,001 $2,577
Life-years
Discounted* 11.024 11.179 0.155
Undiscounted 14.638 14.852 0.214
QALY
Discounted* 8.629 8.802 0.172
Undiscounted 11.458 11.693 0.235
Incremental cost-effectiveness ratios
Cost/LYG
Discounted* $15,530 (Dominant, $42,535)†
Undiscounted $12,059 (Dominant, $32,460)†
Cost/QALY
Discounted* $13,916 (Dominant, $30,890)†
Undiscounted $10,928 (Dominant, $24,457)†
*Discounted at 3% per year.
†Fifth and 95th percentiles from the probabilistic sensitivity analysis.
LYG, life-year gained; QALY, quality-adjusted life-year.
Table 6 Details on cost results (discounted cost per patient) predicted
over 5 years (mean of 100 replications)
Usual care ($) Atorvastatin ($)
Atorvastatin — 5443
Other medications 8752 8541
Acute care 8486 5914
Post–acute care 1551 1277
Routine outpatient care 1200 1214
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was observed in the trial. Given the relatively short time horizon
for events, any long-term changes in these hazards are less rel-
evant. The input distributions for each age were conditional on
sex, baseline mRS was conditional on the type of entry event,
although the frequency of prior medical history assigned to
the patients were not conditional on other characteristics. This
approach does not fully capture the correlations likely to be
observed. Had these characteristics correlated properly, the risks
would become higher among the high risk patients and lower in
those with low risk (e.g., older age are associated with the pres-
ence of other risk factors and vice versa). Thus, this should not
signiﬁcantly affect the overall results. In addition, we did conﬁrm
that the simulation of the SPARCL trial population does replicate
the observed trial event rates. This assumption applies equally to
both cohorts and should not introduce bias.
It should also note that unstable angina was regarded as
initiation of the state of symptomatic coronary disease, so recur-
rence was not considered. Similarly, only one revascularization
procedure was allowed for each patient. A higher rate of recur-
rent hospitalizations and procedures in usual care would increase
the beneﬁcial impact of atorvastatin, lowering its ICER. In addi-
tion, the occurrence of revascularization did not modify the risks
of further cardiovascular events in the model. Although it may
be argued clinically that revascularization procedures should
decrease these risks, the relevant risk equations were derived
based on the ﬁrst event observed in the trial, regardless of any
preceding revascularizations. Therefore, any beneﬁt of these pro-
cedures was already incorporated into the risk equations.
One of the assumptions in this model was that the quality of
life extant at the end of 5 years could be carried forward over the
lifetime. This clearly is not realistic given that other events
and aging can inﬂuence quality of life. As this assumption was
applied to all survivors at the end of 5 years and the numbers of
survivors in both groups were not much different (8123 vs. 8216
Base case
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Figure 2 Tornado diagram of univariate sensitiv-
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for atorvastatin), it should not lead to signiﬁcant bias. Had the
quality of life been extrapolated by taking into account future
events and aging, the ICER would increase. Also, it should be
noted that costs stopped accruing at the end of the time horizon
(5 years). Had these parameters been extrapolated beyond 5
years, the incremental costs would increase due to the survival
beneﬁt, but including these costs in added years of life is currently
not routine practice, so, it has not been done here. The ICER
would increase if these were included.
In the base case, discontinuation was modeled using the rate
observed in the trial (i.e., 5%) as opposed to the rate in actual
practice where it could be as high as 30% [40]. This variation
was explored in the univariate and probabilistic sensitivity analy-
ses and showed little impact on the ICER. This is because the
change in costs and health consequences were in the same direc-
tion (i.e., higher rate of discontinuation led to smaller cost dif-
ference between atorvastatin and usual care groups and smaller
number of events prevented, with corresponding smaller LYG
and QALY gained, compared to base case).
Two important ﬁndings from the SPARCL trial warrant
further discussion. First, there were more hemorrhagic strokes
in the atorvastatin arm (55 vs. 33 with placebo; unadjusted
hazard ratio 1.68, 95% CI 1.09 to 2.59) [41]; yet the overall
stroke rate, including hemorrhagic strokes, was reduced (265 vs.
311 with placebo; adjusted HR 0.84, 95% CI 0.71 to 0.99) [6].
The impact of different stroke types was incorporated in the
model by using treatment-speciﬁc mRS severity ratings (including
stroke case fatality rates which were indicated by mRS of 6).
Simulated patients with strokes of greater severity, such as hem-
orrhagic ones, had poorer quality of life and higher resource use
in the model. Second, the SPARCL trial was underpowered to
ﬁnd a difference in overall mortality (adjusted P = 0.98). Because
of the low mortality from noncardiovascular causes in the trial,
and no single cause of mortality to support a systematic differ-
ence between groups, we estimated this using the data from
Saskatchewan. Cardiovascular mortality was driven by case
fatality rates observed in the trial and longer-term mortality
derived from population data. If only trial-based mortality were
to be used, the difference in LYG and QALYs would decrease,
raising the ICERs.
Although stroke case fatality rates (i.e., mRS = 6) in this
analysis were based on a small number of events (24 vs. 41 with
placebo), these rates were reported having a signiﬁcant difference
[6]. Treatment-speciﬁc MI case fatality rates were not employed
because these were not reported in the trial. We performed a
sensitivity analysis using equivalent stroke case fatality rates for
usual care and atorvastatin; the ICER was increased by approxi-
mately $400 (3%). Thus, we did not expect a signiﬁcant impact
to the ICER had we used treatment-speciﬁc MI case fatality rates.
Despite incorporating data on costs and resource use from
actual practice settings, the external validity of the outcomes may
still be limited to the treatment settings, practice patterns, and
patient characteristics observed in the SPARCL trial. In addition,
because the trial was multinational, the process of care may have
differed in the United States and other countries. Additionally,
the current model allows a speciﬁc set of medications such as
anticoagulants, beta blockers, etc. as part of usual care practice.
In reality, as the pattern of usual care is changing over time, the
model results may not apply in the future. In terms of medication
costs, we applied current AWP costs to all treatments including
atorvastatin, which may overestimate their present and future
values. Payer-speciﬁc discounts and/or rebates as well as future
generic availability of atorvastatin will reduce the long-term
cost of atorvastatin, which would reduce the ICER in favor of
atorvastatin.
Conclusion
The cost-effectiveness of secondary prevention of stroke with a
daily dose of atorvastatin 80 mg is estimated to be economically
favorable. Although treatment with atorvastatin would incur
additional medication cost, this is expected to be partially offset
by savings from hospitalizations and other medications avoided.
Similarly, reduced morbidity from reduction of events is expected
to improve life expectancy and QALYs. Given the signiﬁcant cost
of treatment, a thorough budget impact analysis may be war-
ranted to assess the impact of using daily atorvastatin treatment
on a given payer’s budget.
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